SYNH
NASDAQSyneos Health Inc.
Latest news
25 items- PRMitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.JERSEY CITY, N.J., April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in the United States (U.S.). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S. while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis. "For almost a decade, MT
- PRMitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual MeetingPresentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight results from Phase 3 BouNDless trial in PD and real-world findings from preliminary analysis of RADICAVA® (edaravone) treatment in ALSJERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024. The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).
- PRMitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA's Orphan Drug program is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the U.S. Previously, the FDA granted RADIC
- PRNorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of ManagersNorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
- SECSEC Form 15-12G filed by Syneos Health Inc.15-12G - Syneos Health, Inc. (0001610950) (Filer)
- NEWSSyneos Health Tapped PRA Health Sciences' Colin Shannon as the CEO Succeeding Michelle KeefeOn October 3, 2023, Syneos Health, Inc. (the “Company”) publicly announced that Colin Shannon has been appointed Chief Executive Officer of the Company, effective immediately. Mr. Shannon succeeds Michelle Keefe, who will continue her tenure with the Company as a key member of the Executive Leadership Team. Mr. Shannon and Ms. Keefe will remain on the Board of Directors of the Company. Mr. Shannon does not have any family relationships with any director or executive officer of the Company. In addition, there have been no transactions directly or indirectly involving Mr. Shannon that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act
- SECSEC Form 8-K filed by Syneos Health Inc.8-K - Syneos Health, Inc. (0001610950) (Filer)
- INSIDERZulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERWilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERMonaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERMeyers Kenneth F returned $866,321 worth of shares to the company (25,010 units at $34.64), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERKlitgaard William E returned 7,370 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERConnaughton Bernadette returned $426,345 worth of shares to the company (14,778 units at $28.85), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERBodem Barbara W. returned $151,446 worth of shares to the company (8,385 units at $18.06), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERDineen John M. returned $973,047 worth of shares to the company (27,492 units at $35.39), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERKralowetz Donna Hildebrand returned $130,806 worth of shares to the company (21,288 units at $6.14), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERTucat Christian returned $487,964 worth of shares to the company (50,644 units at $9.64), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDEROlefson Jonathan returned $617,824 worth of shares to the company (64,626 units at $9.56), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERBonello Michael J. returned 51,433 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERBrooks Michael Lee returned $787,588 worth of shares to the company (125,443 units at $6.28), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- INSIDERKeefe Michelle returned $1,545,334 worth of shares to the company (193,442 units at $7.99), closing all direct ownership in the company (SEC Form 4)4 - Syneos Health, Inc. (0001610950) (Issuer)
- SECSEC Form S-8 POS filed by Syneos Health Inc.S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
- SECSEC Form S-8 POS filed by Syneos Health Inc.S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
- SECSEC Form S-8 POS filed by Syneos Health Inc.S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
- SECSEC Form S-8 POS filed by Syneos Health Inc.S-8 POS - Syneos Health, Inc. (0001610950) (Filer)